Back to search results

Remimazolam NeuroImaging Study

This study is looking at how the drug Remimazolam affects your brain activity and thinking. Researchers want to understand its effects while you are resting, experiencing mild pain, and doing a memory task. You would receive Remimazolam through an IV (into your vein) and also experience mild, temporary pain from a nerve stimulator. The study will measure your memory performance about 12-36 hours after your first visit, and your pain levels immediately after MRI scans. Adults aged 18-59 who do not have certain health conditions like chronic pain or significant memory loss may be able to join. The current recruitment status is unclear, and the study aims to enroll 60 participants.

Study design
This is a single-arm study, meaning all participants receive the same treatment. It is a functional MRI study, and 60 participants are planned.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your memory performance will be measured 12-36 hours after your first study session.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07290205

Remimazolam NeuroImaging

Recruiting
EARLY_PHASE1Ages 18–59InterventionalBasic science
Keith M Vogt
~60 participants
Updated 2026-04-02 on ClinicalTrials.gov
What's tested:RemimazolamPeripheral Nerve Stimulation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Explicit memory performance
Measured over Day/Visit 2: 12-36 hours after day 1 session
+1 more outcome measured

Conditions

Anesthesia
Pain
Remimazolam

Explore related trials

Anesthesia ProcedureMemoryPain

Where it's being run

1 sites across 1 states
Pennsylvania1

Study leadership

  • Keith M Vogt, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Pittsburgh

Who to contact

Keith M Vogt, MD, PhD
[email protected]
4126473147
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults 18-59 years of age, who:

Exclusion

have a valid email address and valid phone number throughout the study
free from any non-MRI compatible implants
are pregnant or attempting to conceive
body mass index (BMI) \> 35
significant memory impairment or hearing loss
sleep apnea
chronic pain or frequently taking pain medication (including tramadol)
chronic medical conditions requiring treatment (hypertension, diabetes, high cholesterol)
neurologic disease, including seizures and tremor
psychiatric diagnoses, including anxiety, depression, panic, or PTSD
a history of any of these medical conditions: abnormal heartbeats (cardiac conduction abnormality or arrhythmia), liver or kidney disease, or significant lung disease
severe claustrophobia or MRI intolerance
have metal implants or non-removable metal piercings
having a history of adverse reaction to midazolam (Versed), lorazepam (Ativan) or another benzodiazepine class medication
are allergic to dextran
daily alcohol or heavy alcohol use; history of alcohol abuse
current daily smoker
regular or recent marijuana use (including prescribed/medical marijuana)
illicit drug use, i.e., street drugs
regularly taking: antiepileptics, antidepressants, anti-psychotics, antihistamines, anti-anxiety medication, stimulants, or sleep-aids

What this trial measures

  • Explicit memory performanceDay/Visit 2: 12-36 hours after day 1 session

    Recognition memory testing, using the Remember-Know procedure, in which subjects indicate whether they recognize previously experienced experimental items among novel items (not previously in the experiment). This allows calculation of interdependent measures of recollection \& familiarity using the signal detection statistic, d'. d' is calculated as the cumulative Gaussian distribution of false positive responses subtracted from the cumulative Gaussian distribution of correctly identified previously-experienced items. d' is on a (theoretically infinite) scale of standard deviation units, with negative values representing performance worse than chance guessing and positive values representing stand deviations of performance above chance. Cross-condition comparisons will be the main effect of interest, comparing no drug to remimazolam.

  • subjective pain ratingsDay/Visit 1: immediately after no-drug condition MRI scan and immediately after remimazolam condition MRI scan

    Numerical ratings of pain intensity and unpleasantness will be obtained after each experimental period involving repeated noxious stimulation. Values will be on a 0-10 scale, with 0 representing none and 10 representing the worst possible rating.